Adma Biologics Competitors

Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Adma Biologics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Adma Biologics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
0.173.328.29
Details
Intrinsic
Valuation
LowReal ValueHigh
0.193.818.78
Details
Naive
Forecast
LowNext ValueHigh
0.073.408.37
Details
4 Analysts
Consensus
LowTarget PriceHigh
3.005.7010.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Adma Biologics. Your research has to be compared to or analyzed against Adma Biologics' peers to derive any actionable benefits. When done correctly, Adma Biologics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Adma Biologics.

Adma Biologics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adma Biologics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Adma Biologics and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adma Biologics does not affect the price movement of the other competitor.
Please specify at least 3 valid symbols having historical data to build a meaningful correlation cloud. You can use symbol search above to locate your securities.

Cross Equities Net Income Analysis

Compare Adma Biologics and related stocks such as Regeneron Pharmaceuticals, and Vertex Pharmaceutic Net Income Over Time
Select Fundamental

2010201120122013201420152016201720182019202020212022
REGN(104.5 M)(221.8 M)750.3 M424.4 M348.1 M636.1 M895.5 M1.2 B2.4 B2.1 B3.5 B8.1 B8.7 B
VRTX(754.6 M)29.6 M(107 M)(445 M)(738.6 M)(556.3 M)(112.1 M)263.5 M2.1 B1.2 B2.7 B2.3 B2.5 B

Adma Biologics and related stocks such as Regeneron Pharmaceuticals, and Vertex Pharmaceutic Net Income description

Net income is one of the most important fundamental items in finance. It plays a large role in Adma Biologics financial statement analysis. It represents the amount of money remaining after all of Adma Biologics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.

Adma Biologics Competitive Analysis

The better you understand Adma Biologics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adma Biologics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adma Biologics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
ADMAREGNVRTX
 2.85 
 3.25 
Adma Biologics
 0.12 
 736.23 
Regeneron
 1.01 
 312.98 
Vertex
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Trade Advice
(90 Days Macroaxis Advice)
Number of Shares Shorted
Shares Owned by Insiders
Current Ratio
Profit Margin
EBITDA
Operating Margin
Current Valuation
Cash Flow from Operations
Retained Earnings
Current Asset
Beta
Price to Book
Shares Outstanding
Total Debt
Return On Equity
Price to Earning
Z Score
Shares Owned by Institutions
Return On Asset
Book Value Per Share
Cash and Equivalents
Current Liabilities
Price to Earnings To Growth
Total Asset
Short Ratio
Price to Sales
Market Capitalization
Cash per Share
Net Income
Earnings Per Share
Debt to Equity
Revenue
Working Capital
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Adma Biologics Competition Performance Charts

Complement your Adma Biologics position

In addition to having Adma Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corporate Bonds Thematic Idea Now

Corporate Bonds
Corporate Bonds Theme
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Adma Biologics Correlation with its peers. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for analysis

When running Adma Biologics price analysis, check to measure Adma Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adma Biologics is operating at the current time. Most of Adma Biologics' value examination focuses on studying past and present price action to predict the probability of Adma Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adma Biologics' price. Additionally, you may evaluate how the addition of Adma Biologics to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Is Adma Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adma Biologics. If investors know Adma Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adma Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
639.5 M
Quarterly Revenue Growth YOY
0.99
Return On Assets
(0.11) 
Return On Equity
(0.69) 
The market value of Adma Biologics is measured differently than its book value, which is the value of Adma Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Adma Biologics' value that differs from its market value or its book value, called intrinsic value, which is Adma Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adma Biologics' market value can be influenced by many factors that don't directly affect Adma Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adma Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Adma Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adma Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ADMA
 Stock
  

USD 3.25  0.09  2.85%   

Adma Biologics competes with Regeneron Pharmaceuticals, and Vertex Pharmaceutic; as well as few others. The company conducts business under Healthcare sector and is part of Biotechnology industry. Analyzing Adma Biologics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Adma Biologics to its intrinsic valuation because they are able to contrast its competitors on a relative basis.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Adma Biologics competition on your existing holdings. Please continue to Adma Biologics Correlation with its peers.
  
As of November 26, 2022, Return on Investment is expected to decline to -30.19. In addition to that, Return on Average Assets is expected to decline to -31.95. Adma Biologics Total Assets are projected to increase significantly based on the last few years of reporting. The past year's Total Assets were at 276.25 Million. The current year Current Assets is expected to grow to about 225.2 M, whereas Revenue to Assets are forecasted to decline to 0.25.